Canada: Is The Competition Bureau Targeting You? New IP Enforcement Guidelines

On June 9, 2015, the Canadian Competition Bureau released updated draft Intellectual Property Enforcement Guidelines (IPEGs) for public comment. The comment period is open until August 10, 2015. It is the third publication of the IPEGs since early 2014, evincing the Bureau's increased interest in the IP/competition interface.

What are IPEGs?

While competition law seeks to restrain behaviour that would harm vigorous competition, intellectual property laws are designed to exclude competitors from the marketplace. The market exclusivity resulting from IP protection encourages innovation. Despite their inherent conflict, the Bureau views IP laws and competition laws as two "complementary instruments of government policy".

The Bureau publishes the IPEGs to provide insight into and examples of how the Bureau determines whether conduct involving IP raises concerns under the competition laws. The original IPEGs were released in 2000. The Bureau released a preliminary version of the updated IPEGs in September 2014, which primarily addressed amendments to the Competition Act in 2009 and sought to ensure that the IPEGs were consistent with other Bureau guidelines released since the 2009 amendments. All versions of the IPEGs contain examples of how the Bureau might address situations that engage IP and competition laws.

New Analysis in the June 2015 Draft

The June 2015 Draft provides commentary and examples for three additional areas that could attract competition review: patent assertion entities (PAEs), patent litigation settlement agreements (primarily pharmaceutical) and standard essential patents (SEPs), which are patents that protect technology essential to an industry's standardized technology, so that all manufacturers' products meet certain performance and safety standards and can interoperate. Examples 1-9 were previously published.

The June 2015 Draft adds new Examples 10 – 18, which illustrate how the Bureau might address potentially anticompetitive behaviour in the three new areas identified above, as follows:

  • Example 10 addresses PAEs.
  • Examples 11, 12, 13A and 13B address pharmaceutical litigation settlements between brand and generic firms.
  • Examples 14 to 18 address SEPs.

Bureau Review of Patent Assertion Entity Behaviour

PAEs typically do not use patents they own for their own products or production, but instead assert the patents against other firms in litigation.

In Example 10, the entity sent thousands of notices to businesses stating that the PAE had proof that the recipient was infringing one or more of its patents, and demanding that each recipient pay a licensing fee to avoid litigation. Some businesses that received letters complained to the Bureau that the notices were false or misleading, as they had not infringed the patents.

The Bureau's analysis considered whether the PAE made materially false or misleading representations. If the assertions were truthful, no further action would be required and the assertions would not attract further review. If the assertions were made indiscriminately or indifferently, the assertions could raise concerns under the reviewable matters sections (74.01(1)(a)) and the criminal provisions (section 52(1)) of the Competition Act.

Bureau Review of Pharmaceutical Settlements

A large proportion of Canadian patent litigation involves pharmaceutical companies, typically "brand" and "generic" companies, litigating the issues of whether the brand's patent's claims are invalid or infringed by the generic. Many of these cases are governed by the Patented Medicines (Notice of Compliance) (PM(NOC)) Regulations, and many PM(NOC) cases settle before a judge renders a decision that evaluates the non-infringement or invalidity allegations.

The Bureau has taken the general position that settlements that permit a generic to enter the market prior to patent expiration, assuming no payment is provided by the brand to the generic, do not lessen competition. These settlements will not attract Bureau review. The Bureau calls these "entry-split" settlements.

If a brand provides payment to a generic in a settlement, and also allows the generic to enter the market before patent expiration, the Bureau will review the settlement under the Competition Act. In the Bureau's view, the payment could harm competition if the payment serves to delay generic market entry. The Bureau would generally review such a settlement under the arrangements-between-competitors provisions of the Competition Act (section 90.1). However, the Bureau may also review a settlement under the abuse-of-dominant-position provisions of the Competition Act (section 79), if (i) the parties are dominant or jointly dominant, (ii) the agreement results in or facilitates conduct that has a negative effect on competitors that is exclusionary, predatory or disciplinary, and (iii) the agreement would substantially lessen competition in a market. The Bureau could review a settlement under the conspiracy provisions of the Competition Act (section 45); indeed the Commissioner sparked concern from the business community in seeming to suggest in September 2014 that such an approach could be the norm. However, the Bureau has emphasized in the June 2015 Draft that the circumstances for a criminal investigation "would occur on a limited basis" and only when the intent was to fix prices, allocate markets or restrict output.

Bureau Review of Standard Essential Patents

The Bureau recognizes that industries typically develop technical standards, which can provide procompetitive benefits, such as decreasing production costs, increasing efficiency and consumer choice and fostering innovation. However, the Bureau is concerned that the development of such standards can pose competition concerns, by reducing price competition and firm competitiveness when other firms are denied access to the standard. Examples 14 to 18 address a number of possible situations, including a "patent ambush" by a patent owner that did not disclose the importance of its IP in a standard (Example 15), reneging on a licensing commitment (Example 16) and seeking an injunction after making a licensing commitment (Example 18).

How could the New Guidelines Affect You?

In the case of pharmaceutical patent litigation, the Bureau has signalled an increased interest in reviewing settlements by updating the IPEGs and publishing a white paper in September 2014 and in the Commissioner's address at the Global Antitrust Institute conference on September 23, 2014. The Bureau is clearly considering ways to facilitate increased scrutiny.

Despite this interest in identifying and reviewing pharmaceutical settlements, the Bureau finds itself in a challenging position. In Canada, there is no legislative requirement for competition review of pharmaceutical settlements. The Bureau may review settlements or arrangements if they are submitted voluntarily or otherwise come to its attention. By contrast, in the United States, pharmaceutical patent settlements generally must be reported to the Federal Trade Commission (FTC) and all pharmaceutical patent settlements are subject to review by the FTC.

Notwithstanding legislative limitations, given the positions taken by the Bureau in recent publications, we expect the Bureau to become more aggressive in finding ways to access and review such settlements. Once aware of an agreement, the Bureau does have the ability to seek compulsory orders for parties to provide information to it (including, potentially, parties' respective assessments as to the strength of the patent in issue), with a view to investigating, and potentially challenging, a particular settlement as violating the Competition Act.

In the case of PAEs and SEPs, the Bureau is unlikely to be aware of potentially anti-competitive activities absent complaint by affected firms. Accordingly, increased Bureau review is unlikely unless affected firms take steps to notify the Bureau.

Want to Weigh In?

The Bureau has invited interested parties to provide comments on the draft updated IPEGs, by August 10, 2015. See the Bureau's release at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.